The value of serum CYFRA21-1, CA125 and CA72-4 in clinical staging esophageal cancer

Objectives: To investigate the clinical value of the serum levels of CA125, CA72-4 and CYFRA21-1 in staging of esophageal cancer patients. Methods: The serum levels of CA125, CA72-4 and CYFRA21-1 in 190 esophageal cancer patients and 79 healthy controls were measured by radioimmunoassay. The clinical pathological parameters in esophageal cancer patients were collected and analyzed. Results: The serum levels of CYFRA21-1, CA72-4 and CA125 in esophageal cancer patients were increasing as their staging increased. The CYFRA21-1 levels in patients in stage of Ⅱ a, Ⅲ, Ⅳ, and the lymph node positive group had statistical difference with the healthy control group (P < 0.05). The CA125 levels in patients between stages of Ⅳ and Ⅰ had statistical difference (P< 0.05). The CA72-4 levels in patients in all stages had no statistical significant. Conclusion: The serum CYFRA21-1 could be used to identify the early stage (stage 0 and Ⅰ) and advanced stage (stage Ⅱ b, Ⅲ and Ⅳ). The serum CA125 might be used to identify the early stage and advanced stage, and the serum CA125 is obviously correlated with pT staging in esophageal cancer patients. (authors)